InSyBio is a global leader in biotechnology for precision medicine and nutrition, offering biosignature identification and diagnostic/prognostic tests for conditions including cancer, neurodegenerative diseases, cardiovascular diseases, chronic pain, and nutrition. Their advanced bioinformatics and machine learning biomarker discovery solution allows pharmaceutical and nutrition companies to personalize their approach. On the other hand, InSysBio (formerly known as the Institute for Systems Biology Moscow) is a company specializing in Quantitative Systems Pharmacology (QSP) established in 2004. Their experienced team provides QSP modeling and simulation services to assist in making critical decisions at various stages of drug development for over a decade.